AU2006294600A1 - Alkoxy indolinone based protein kinase inhibitors - Google Patents
Alkoxy indolinone based protein kinase inhibitors Download PDFInfo
- Publication number
- AU2006294600A1 AU2006294600A1 AU2006294600A AU2006294600A AU2006294600A1 AU 2006294600 A1 AU2006294600 A1 AU 2006294600A1 AU 2006294600 A AU2006294600 A AU 2006294600A AU 2006294600 A AU2006294600 A AU 2006294600A AU 2006294600 A1 AU2006294600 A1 AU 2006294600A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- tautomer
- salt
- represented
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 Alkoxy indolinone Chemical compound 0.000 title claims description 48
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title description 5
- 239000003909 protein kinase inhibitor Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 91
- 150000003839 salts Chemical class 0.000 claims description 38
- 229940002612 prodrug Drugs 0.000 claims description 33
- 239000000651 prodrug Substances 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 102000001253 Protein Kinase Human genes 0.000 claims description 13
- 150000001408 amides Chemical class 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 108060006633 protein kinase Proteins 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 108091008605 VEGF receptors Proteins 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 4
- 150000001735 carboxylic acids Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims description 4
- 150000002170 ethers Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 150000002576 ketones Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 108091008606 PDGF receptors Proteins 0.000 claims description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000001769 aryl amino group Chemical group 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 101100244083 Arabidopsis thaliana PKL gene Proteins 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 29
- 239000002253 acid Substances 0.000 description 23
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 238000002953 preparative HPLC Methods 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 239000007858 starting material Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- QSQYNJMCDGEKIN-UHFFFAOYSA-N 1-(1h-pyrrol-2-yl)-3h-indol-2-one Chemical class O=C1CC2=CC=CC=C2N1C1=CC=CN1 QSQYNJMCDGEKIN-UHFFFAOYSA-N 0.000 description 3
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QUTSKIWJUHDULC-UHFFFAOYSA-N methyl 4-amino-3-hydroxybutanoate Chemical compound COC(=O)CC(O)CN QUTSKIWJUHDULC-UHFFFAOYSA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- RBHBOUYXUXWCNJ-WDZFZDKYSA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxylic acid Chemical compound OC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C RBHBOUYXUXWCNJ-WDZFZDKYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N DL-isoserine Natural products NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000007705 chemical test Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LFVPHXOOLUCFFB-UHFFFAOYSA-N methyl 3-amino-2-hydroxypropanoate Chemical compound COC(=O)C(O)CN LFVPHXOOLUCFFB-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003566 phosphorylation assay Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YJJOTLPSZGROJU-BXBOZWQASA-N (2s)-2-ethoxy-4-[[5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carbonyl]amino]butanoic acid Chemical compound CCO[C@H](C(O)=O)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C YJJOTLPSZGROJU-BXBOZWQASA-N 0.000 description 1
- KIQYJKFRWNIWPX-DZXKJOIRSA-N (2s)-4-[[5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carbonyl]amino]-2-methoxybutanoic acid Chemical compound CO[C@H](C(O)=O)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KIQYJKFRWNIWPX-DZXKJOIRSA-N 0.000 description 1
- AMMBUJFMJOQABC-UHFFFAOYSA-N 1-carboxypropylazanium;chloride Chemical compound Cl.CCC(N)C(O)=O AMMBUJFMJOQABC-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- RQOMQNCNBWUXNX-ZSOIEALJSA-N 2-ethoxy-3-[[5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carbonyl]amino]propanoic acid Chemical compound CCOC(C(O)=O)CNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C RQOMQNCNBWUXNX-ZSOIEALJSA-N 0.000 description 1
- UZFKBMGMRNOCRR-QPEQYQDCSA-N 3-[[5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carbonyl]amino]-2-methoxypropanoic acid Chemical compound COC(C(O)=O)CNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C UZFKBMGMRNOCRR-QPEQYQDCSA-N 0.000 description 1
- KZRJYNLJOIKOBP-SXGWCWSVSA-N 3-ethoxy-4-[[5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carbonyl]amino]butanoic acid Chemical compound CCOC(CC(O)=O)CNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KZRJYNLJOIKOBP-SXGWCWSVSA-N 0.000 description 1
- GJXYPLVYBJRODH-BOPFTXTBSA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-n-(2-methoxy-3-morpholin-4-yl-3-oxopropyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCC(OC)C(=O)N1CCOCC1 GJXYPLVYBJRODH-BOPFTXTBSA-N 0.000 description 1
- PVYCHAXCKDLTIC-UNOMPAQXSA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-n-(2-methoxy-4-oxo-4-pyrrolidin-1-ylbutyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCC(OC)CC(=O)N1CCCC1 PVYCHAXCKDLTIC-UNOMPAQXSA-N 0.000 description 1
- AYLYYUCLGLWSMF-UHWDDTASSA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-n-[(3s)-3-methoxy-4-morpholin-4-yl-4-oxobutyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound O=C([C@H](CCNC(=O)C=1C(=C(\C=C/2C3=CC(F)=CC=C3NC\2=O)NC=1C)C)OC)N1CCOCC1 AYLYYUCLGLWSMF-UHWDDTASSA-N 0.000 description 1
- UNQYAAAWKOOBFQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[4-chloro-3-(trifluoromethoxy)phenoxy]-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=C(Cl)C(OC(F)(F)F)=C1 UNQYAAAWKOOBFQ-UHFFFAOYSA-N 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 101000851005 Mus musculus Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- GEDRSNCJXPPNFI-WCCKRBBISA-N methyl (2s)-4-amino-2-hydroxybutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](O)CCN GEDRSNCJXPPNFI-WCCKRBBISA-N 0.000 description 1
- VHMGYHFYSWICSP-UHFFFAOYSA-N methyl 3-amino-2-hydroxypropanoate;hydrochloride Chemical class Cl.COC(=O)C(O)CN VHMGYHFYSWICSP-UHFFFAOYSA-N 0.000 description 1
- HXGXFXBXPGNZKO-UHFFFAOYSA-N methyl 4-amino-2-hydroxybutanoate Chemical compound COC(=O)C(O)CCN HXGXFXBXPGNZKO-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- KXECLDXTZBKCPW-PDGQHHTCSA-N n-(2-ethoxy-3-morpholin-4-yl-3-oxopropyl)-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCC(OCC)C(=O)N1CCOCC1 KXECLDXTZBKCPW-PDGQHHTCSA-N 0.000 description 1
- VUWAKJWQZWPLMV-YBEGLDIGSA-N n-[3-(dimethylamino)-2-ethoxy-3-oxopropyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CCOC(C(=O)N(C)C)CNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C VUWAKJWQZWPLMV-YBEGLDIGSA-N 0.000 description 1
- HXWVCRBABUROFU-WQRHYEAKSA-N n-[4-(dimethylamino)-2-ethoxy-4-oxobutyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CN(C)C(=O)CC(OCC)CNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C HXWVCRBABUROFU-WQRHYEAKSA-N 0.000 description 1
- SPVIIPXHQXUWRM-YVLHZVERSA-N n-[4-(dimethylamino)-2-methoxy-4-oxobutyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CN(C)C(=O)CC(OC)CNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C SPVIIPXHQXUWRM-YVLHZVERSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71947405P | 2005-09-22 | 2005-09-22 | |
| US60/719,474 | 2005-09-22 | ||
| PCT/US2006/036946 WO2007038251A1 (en) | 2005-09-22 | 2006-09-21 | Alkoxy indolinone based protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006294600A1 true AU2006294600A1 (en) | 2007-04-05 |
Family
ID=37900093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006294600A Abandoned AU2006294600A1 (en) | 2005-09-22 | 2006-09-21 | Alkoxy indolinone based protein kinase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20090305382A1 (https=) |
| EP (1) | EP1926725A4 (https=) |
| JP (1) | JP2009508971A (https=) |
| KR (1) | KR20080046701A (https=) |
| CN (1) | CN101282965A (https=) |
| AU (1) | AU2006294600A1 (https=) |
| BR (1) | BRPI0616378A2 (https=) |
| CA (1) | CA2621809A1 (https=) |
| RU (1) | RU2008110083A (https=) |
| WO (1) | WO2007038251A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009508971A (ja) * | 2005-09-22 | 2009-03-05 | ザ スクリプス リサーチ インスティテュート | アルコキシインドリノン系プロテインキナーゼ阻害剤 |
| JP2010502741A (ja) * | 2006-09-11 | 2010-01-28 | キュリス，インコーポレイテッド | Ｐｔｋインヒビターとしての亜鉛結合部分を含む置換２−インドリノン |
| ES2565683T3 (es) * | 2006-09-15 | 2016-04-06 | Xcovery, Inc. | Compuestos inhibidores de quinasa |
| IN2014MN02105A (https=) | 2012-04-20 | 2015-09-11 | Annji Pharm Co Ltd | |
| AU2015226206B2 (en) | 2014-03-07 | 2017-03-16 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection |
| CA2979490C (en) | 2015-03-16 | 2023-07-18 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| EP3512556B1 (en) | 2016-09-13 | 2021-08-18 | F. Hoffmann-La Roche AG | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| CN110016052B (zh) * | 2018-01-08 | 2021-09-28 | 四川海思科制药有限公司 | N-去乙基舒尼替尼的磷酰胺衍生物及其制备方法 |
| JP2022525522A (ja) | 2019-03-25 | 2022-05-17 | エフ．ホフマン－ラ ロシュ アーゲー | Ｈｂｖコアタンパク質アロステリック修飾剤の化合物の固体形態 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US72934A (en) * | 1867-12-31 | Improvement in marking-gauge fob sswim-mgohines | ||
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| TWI259081B (en) * | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| MXPA06006049A (es) * | 2003-11-26 | 2007-05-24 | Scripps Research Inst | Inhibidores de proteina quinasa avanzados a base de indolinona. |
| JP2009508971A (ja) * | 2005-09-22 | 2009-03-05 | ザ スクリプス リサーチ インスティテュート | アルコキシインドリノン系プロテインキナーゼ阻害剤 |
-
2006
- 2006-09-21 JP JP2008532411A patent/JP2009508971A/ja not_active Withdrawn
- 2006-09-21 CA CA002621809A patent/CA2621809A1/en not_active Abandoned
- 2006-09-21 CN CNA2006800352235A patent/CN101282965A/zh active Pending
- 2006-09-21 EP EP06815164A patent/EP1926725A4/en not_active Withdrawn
- 2006-09-21 WO PCT/US2006/036946 patent/WO2007038251A1/en not_active Ceased
- 2006-09-21 RU RU2008110083/04A patent/RU2008110083A/ru not_active Application Discontinuation
- 2006-09-21 BR BRPI0616378-5A patent/BRPI0616378A2/pt not_active IP Right Cessation
- 2006-09-21 US US11/991,971 patent/US20090305382A1/en not_active Abandoned
- 2006-09-21 KR KR1020087008492A patent/KR20080046701A/ko not_active Withdrawn
- 2006-09-21 AU AU2006294600A patent/AU2006294600A1/en not_active Abandoned
- 2006-09-21 US US11/525,291 patent/US7629339B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007038251A1 (en) | 2007-04-05 |
| BRPI0616378A2 (pt) | 2011-06-21 |
| CA2621809A1 (en) | 2007-04-05 |
| CN101282965A (zh) | 2008-10-08 |
| EP1926725A4 (en) | 2010-10-06 |
| EP1926725A1 (en) | 2008-06-04 |
| US7629339B2 (en) | 2009-12-08 |
| US20070072934A1 (en) | 2007-03-29 |
| JP2009508971A (ja) | 2009-03-05 |
| KR20080046701A (ko) | 2008-05-27 |
| US20090305382A1 (en) | 2009-12-10 |
| RU2008110083A (ru) | 2009-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114981268B (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
| MX2009000769A (es) | Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak. | |
| AU2010212560B2 (en) | Derivatives of azaindoles as inhibitors of protein kinases Abl and Src | |
| EP2393814A1 (en) | Pyrrolopyrimidinyl axl kinase inhibitors | |
| AU2008237717A1 (en) | 2-morpholin-4-yl-pyrimidines as PI3K inhibitors | |
| WO2014135028A1 (zh) | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 | |
| Liu et al. | Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study | |
| AU2006294600A1 (en) | Alkoxy indolinone based protein kinase inhibitors | |
| Zhang et al. | Discovery of a series of N-(5-(quinolin-6-yl) pyridin-3-yl) benzenesulfonamides as PI3K/mTOR dual inhibitors | |
| WO2005081997A2 (en) | Isothiazole based protein kinase inhibitors | |
| CA2635360A1 (en) | Amino acid derivatives of indolinone based protein kinase inhibitors | |
| MX2007014810A (es) | Inhibidores de la proteina quinasa mejoradas a base de indolinona. | |
| WO2005053692A1 (en) | Advanced quinolinone based protein kinase inhibitors | |
| CN119490494B (zh) | 芳基取代的五元氮杂环酰胺类衍生物及其用途 | |
| CN115340502B (zh) | Bcl-xl抑制剂及其制备方法和用途 | |
| MX2008008492A (en) | Amino acid derivatives of indolinone based protein kinase inhibitors | |
| WO2021168521A1 (en) | Inhibitors of necroptosis | |
| CN108084179A (zh) | 一种具有螺环结构的化合物、其制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |